Diadema Partners LP Buys Shares of 50,620 Apogee Therapeutics, Inc. (NASDAQ:APGE)

Diadema Partners LP purchased a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,620 shares of the company's stock, valued at approximately $2,293,000. Apogee Therapeutics accounts for approximately 1.0% of Diadema Partners LP's investment portfolio, making the stock its 21st biggest holding. Diadema Partners LP owned approximately 0.11% of Apogee Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Barclays PLC boosted its position in shares of Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company's stock worth $21,443,000 after acquiring an additional 287,243 shares during the last quarter. Geode Capital Management LLC lifted its stake in Apogee Therapeutics by 11.2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company's stock worth $48,401,000 after purchasing an additional 82,978 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Apogee Therapeutics by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company's stock valued at $1,736,000 after purchasing an additional 1,212 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Apogee Therapeutics by 22.2% during the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company's stock valued at $448,000 after purchasing an additional 1,796 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Apogee Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company's stock valued at $432,000 after purchasing an additional 892 shares in the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Apogee Therapeutics

In other news, CEO Michael Thomas Henderson sold 10,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. The trade was a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 3,860 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the transaction, the insider now directly owns 247,173 shares in the company, valued at approximately $8,952,606.06. This trade represents a 1.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,970 shares of company stock worth $1,241,701. Insiders own 36.10% of the company's stock.

Wall Street Analysts Forecast Growth

APGE has been the subject of a number of research reports. Wedbush reissued an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Finally, Citigroup initiated coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics has an average rating of "Buy" and an average price target of $92.17.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE traded down $0.20 during trading hours on Friday, hitting $36.85. 578,730 shares of the company's stock traded hands, compared to its average volume of 512,343. The firm has a market capitalization of $1.66 billion, a P/E ratio of -15.23 and a beta of 1.72. The business has a fifty day moving average price of $35.15 and a 200-day moving average price of $42.81. Apogee Therapeutics, Inc. has a 1 year low of $26.20 and a 1 year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). As a group, equities analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.